
CAPRICOR THERAPEUTICS, INC.
93
Recent developments highlight Capricor's ongoing clinical progress, regulatory interactions, and strategic positioning ahead of the FDA decision on Deramiocel.
- Capricor held its Q2 2026 earnings call discussing clinical progress and regulatory status of Deramiocel [N1].
- The company is advancing FDA approval path discussions for Deramiocel as a treatment for Duchenne muscular dystrophy [N3].
- Presentation of 24-month HOPE-3 clinical trial data showing functional gains in DMD patients was made at a scientific conference [N7].
- Q1 2026 earnings transcripts and call highlights provided updates on clinical development and financial status [N4][N5].
- Capricor continues to emphasize the potential of Deramiocel to address both skeletal and cardiac muscle manifestations of DMD [N2].
- The company is preparing for potential commercialization and expanding manufacturing capabilities subject to existing distribution agreements [N1].
Capricor Therapeutics focuses on developing cell and exosome-based therapies targeting Duchenne muscular dystrophy (DMD), a rare genetic disorder causing progressive muscle degeneration and cardiac complications. The company's lead product candidate, Deramiocel, is a cell therapy composed of cardiosphere-derived cells designed to slow disease progression through immunomodulatory and anti-fibrotic mechanisms. Deramiocel is undergoing FDA review with a PDUFA target action date in August 2026. Clinical trials including the Phase 3 HOPE-3 study have demonstrated statistically significant benefits in slowing upper limb decline and improving cardiac function. Capricor also advances an exosome platform technology for therapeutic applications, including a SARS-CoV-2 vaccine candidate in early clinical development. The company has no approved products yet and plans to commercialize Deramiocel in the US and seek partnerships internationally. Financially, Capricor maintains strong liquidity with over $44 million in cash and equivalents as of September 2026 and reported a net loss of $42.7 million for the nine months ended September 30, 2026.
Capricor Therapeutics, Inc. is a biotechnology company developing cell and exosome-based therapies primarily for Duchenne muscular dystrophy (DMD). Its lead candidate, Deramiocel, is a cell therapy designed to slow progression of skeletal and cardiac muscle degeneration in DMD. The company has conducted multiple clinical trials, including the Phase 3 HOPE-3 trial, which showed statistically significant slowing of disease progression and cardiac function benefits. Deramiocel's Biologics License Application is under FDA review with a PDUFA date of August 22, 2026. Capricor also develops an exosome platform for therapeutics and vaccines. Financially, as of September 30, 2026, the company reported $44.3 million in cash and equivalents, a current ratio of 6.77, and a net loss of $42.7 million for the nine months ended. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Capricor's lead candidate, Deramiocel, has demonstrated statistically significant clinical benefits in slowing disease progression and improving cardiac function in DMD patients, supported by multiple clinical trials including Phase 3 HOPE-3. The FDA's acceptance of the BLA with Priority Review and a PDUFA date in August 2026 marks a critical regulatory milestone. The company's exosome platform offers potential for expanding therapeutic applications beyond DMD, including infectious diseases. Strong liquidity and strategic collaborations provide resources to advance development and commercialization efforts.
Risks include the absence of approved products to date and the regulatory uncertainty inherent in the FDA review process, especially following a prior Complete Response Letter requiring additional clinical data. The clinical data, while statistically significant, may face scrutiny regarding robustness and long-term efficacy. Commercialization depends on successful regulatory approval and market acceptance. The company operates at a net loss with ongoing funding needs. Competition in the biotechnology sector and challenges in scaling manufacturing and commercial infrastructure also present risks.
Capricor's moat derives from its proprietary cell therapy technology based on cardiosphere-derived cells and its exosome platform, supported by extensive clinical trial data and collaborations with leading research institutions. The company's focus on Duchenne muscular dystrophy addresses a significant unmet medical need with limited existing therapies, particularly targeting both skeletal and cardiac muscle complications. Regulatory progress with an FDA Biologics License Application under Priority Review and a robust clinical development program further strengthen its competitive position. Manufacturing capabilities and strategic partnerships for commercialization also contribute to barriers to entry for competitors.
• Regulatory Risk: The FDA previously issued a Complete Response Letter requesting additional clinical data, indicating regulatory challenges remain for Deramiocel approval.
• Clinical Data Uncertainty: While clinical trials have shown statistically significant results, the data may be considered fragile or require further validation for regulatory and commercial acceptance.
• Financial Risk: The company reported a net loss of $42.7 million for the nine months ended September 30, 2026, and depends on continued funding to support operations and commercialization efforts.
• Commercialization Risk: Successful commercialization depends on regulatory approval, manufacturing scale-up, and market acceptance, with potential challenges in building commercial infrastructure and securing partnerships.
Business trends: Continued clinical data dissemination and regulatory engagement for Deramiocel in DMD; expansion of exosome platform research.
Execution milestones: FDA decision on Deramiocel BLA; presentation of clinical trial data; manufacturing and commercialization preparations.
Key risks: Regulatory approval uncertainty; clinical data robustness; financial sustainability; commercialization challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Capricor Therapeutics, Inc. is a biotechnology company focused on developing and potentially commercializing cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
- The lead product candidate is Deramiocel, a cell therapy composed of cardiosphere-derived cells (CDCs) designed to slow progression of cardiac and skeletal muscle complications in DMD.
- Deramiocel's mechanism involves immunomodulatory, anti-inflammatory, pro-angiogenic, and anti-fibrotic activities mediated partly by exosomes containing bioactive molecules.
- DMD is a rare genetic disorder causing progressive muscle degeneration and premature death, with cardiac complications being a leading cause of mortality.
- Deramiocel is in regulatory review by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026, following a Complete Response Letter and subsequent resubmission.
- The company has conducted multiple clinical trials including Phase 3 HOPE-3, Phase 2 HOPE-2, and earlier studies, showing statistically significant slowing of disease progression and cardiac function benefits.
- HOPE-3 trial showed 54% slowing of upper limb progression and 91% slowing of decline in left ventricular ejection fraction compared to placebo, with statistical significance.
- Additional analyses from HOPE-3 demonstrated reduction in myocardial fibrosis and improvement in cardiac MRI measures.
- Capricor is also developing an exosome-based platform (StealthX) for therapeutics and vaccines, including a SARS-CoV-2 vaccine candidate in Phase 1 clinical study.
- The company has collaborations with NIH, NIAID, Johns Hopkins University, Department of Defense, and others to support exosome research and development.
- Capricor has no products approved for commercial sale yet and plans to commercialize Deramiocel in the US and seek partners for international markets.
- The company has received approximately $600 million in funding from equity financings, collaborations, grants, and government programs.
- Financial snapshot as of September 30, 2026: cash and equivalents $44.3 million, current assets $202.3 million, current liabilities $29.9 million, net loss $42.7 million for the nine months ended September 30, 2026.
- Liquidity ratios as of September 30, 2026: current ratio 6.77, cash ratio 4.13, indicating strong short-term liquidity.
- Earnings per share basic and diluted were -$0.73 for the nine months ended September 30, 2026.
- Recent news highlights include Q2 2026 earnings call, FDA approval path discussions, and presentation of clinical data from HOPE-3 trial.
- The company is preparing for potential commercialization and expanding manufacturing and commercial infrastructure subject to existing distribution rights.
- Capricor's strategic priorities include advancing Deramiocel regulatory process, expanding indications, advancing exosome platform, and pursuing collaborations to accelerate development.
Generated 2026-11-10
- S1 | 2026-03-17 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-08-13 | www.nasdaq.com | Capricor Therapeutics Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/capricor-therapeutics-q2-earnings-call-highlights
- N2 | 2026-07-10 | www.nasdaq.com | Relative Strength Alert For Capricor Therapeutics | https://www.nasdaq.com/articles/relative-strength-alert-capricor-therapeutics
- N3 | 2026-06-11 | www.nasdaq.com | Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy | https://www.nasdaq.com/articles/capricor-therapeutics-eyes-fda-approval-path-duchenne-cell-therapy
- N4 | 2026-05-14 | www.nasdaq.com | Capricor (CAPR) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/capricor-capr-q1-2026-earnings-transcript
- N5 | 2026-05-12 | www.nasdaq.com | Capricor Therapeutics Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/capricor-therapeutics-q1-earnings-call-highlights
- N6 | 2026-05-12 | www.nasdaq.com | After-Hours Earnings Report for May 12, 2026 : FNV, NXT, OKLO, KRMN, REZI, ATRO, CAPR, AIP, EVLV, KURA, RLMD, GAIN | https://www.nasdaq.com/articles/after-hours-earnings-report-may-12-2026-fnv-nxt-oklo-krmn-rezi-atro-capr-aip-evlv-kura
- N7 | 2026-04-23 | www.nasdaq.com | Capricor Highlights HOPE-3 Data Showing Functional Gains In Duchenne Muscular Dystrophy | https://www.nasdaq.com/articles/capricor-highlights-hope-3-data-showing-functional-gains-duchenne-muscular-dystrophy
- N8 | 2026-03-13 | www.nasdaq.com | Capricor (CAPR) Q4 2025 Earnings Call Transcript | https://www.nasdaq.com/articles/capricor-capr-q4-2025-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


